FRK
Tyrosine-protein kinase FRK
As of the edition of 20 October 2026, FRK (tyrosine-protein kinase FRK, UniProt P42685) has 6 drugs tested at it and 7 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P42685
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Digestive system; Blood and lymph; Immune system; Lungs and airways; Skin and connective tissue; Urinary and reproductive; Hormones
- Registered trials of its drugs
- 583
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dasatinib anhydrous | Marketed | Phase 4 | Ended 2026 |
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| ENMD-981693 | Went quiet | Phase 2 | none listed |
| Ilorasertib | Stopped | Phase 2 | none listed |
| TG100-801 | Stopped | Phase 2 | none listed |
| XL-228 | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Engaged | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Bayer | Route B |
| Bristol Myers Squibb | Route B |
| Exelixis | Route A |
The other 4 companies at FRK
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at FRK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.